Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: guger m. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A, Kleinschnitz C, Rauer S, Kuhle J, Stangel M, Weber F, Uhr M, Linnebank M, Wildemann B, Jarius S, Guger M, Ayzenberg I, Chan A, Zettl U, Wiendl H, Pilz G, Hitzl W, Weber JR, Kraus J. Harrer A, et al. Among authors: guger m. Mult Scler. 2013 Aug;19(9):1209-12. doi: 10.1177/1352458512463483. Epub 2012 Oct 23. Mult Scler. 2013. PMID: 23093485
Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics.
Berger T, Jacobi C, Haas J, Ransmayr G, Guger M, Zettl UK, Di Pauli F, Taumberger B, Wietek S, Meuer S, Reindl M, Giese T. Berger T, et al. Among authors: guger m. J Neuroimmunol. 2014 Dec 15;277(1-2):145-52. doi: 10.1016/j.jneuroim.2014.10.001. Epub 2014 Oct 12. J Neuroimmunol. 2014. PMID: 25454729
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Epidemiology of Multiple Sclerosis in Austria.
Salhofer-Polanyi S, Cetin H, Leutmezer F, Baumgartner A, Blechinger S, Dal-Bianco A, Altmann P, Bajer-Kornek B, Rommer P, Guger M, Leitner-Bohn D, Reichardt B, Alasti F, Temsch W, Stamm T. Salhofer-Polanyi S, et al. Among authors: guger m. Neuroepidemiology. 2017;49(1-2):40-44. doi: 10.1159/000479696. Epub 2017 Aug 19. Neuroepidemiology. 2017. PMID: 28848208
Month-of-birth-effect in multiple sclerosis in Austria.
Walleczek NK, Frommlet F, Bsteh G, Eggers C, Rauschka H, Koppi S, Assar H, Ehling R, Birkl C, Salhofer-Polanyi S, Baumgartner A, Blechinger S, Buchinger D, Sellner J, Kraus J, Moser H, Mayr M, Guger M, Rathmaier S, Raber B, Liendl H, Hiller MS, Parigger S, Morgenstern G, Kempf I, Spiss HK, Meister B, Heine M, Cisar A, Bachler H, Khalil M, Fuchs S, Enzinger C, Fazekas F, Leutmezer F, Berger T, Kristoferitsch W, Aboulenein-Djamshidian F. Walleczek NK, et al. Among authors: guger m. Mult Scler. 2019 Dec;25(14):1870-1877. doi: 10.1177/1352458518810924. Epub 2018 Nov 22. Mult Scler. 2019. PMID: 30463473
Real-life use of oral disease-modifying treatments in Austria.
Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR). Guger M, et al. Acta Neurol Scand. 2019 Jul;140(1):32-39. doi: 10.1111/ane.13097. Epub 2019 Apr 22. Acta Neurol Scand. 2019. PMID: 30958901 Free PMC article.
48 results